Emerging from the UK, retatrutide, a new molecule, is generating considerable excitement within the medical community regarding its ability for physique control . This dual GIP and GLP-1 agent agonist appears to offer a significant benefit over current therapies, showing encouraging results in preliminary clinical assessments. Researchers suggest i